The Latest Cardiac and Vascular News
The application includes data from the STTAR clinical study with a one-year follow-up period. NEWTOWN, Pa. Jan. 29, 2021 / PRNewswire / – Micro Interventional Devices, Inc. ™ (MID) announced today that it has provided the technical documentation required for CE approval of its MIA-T ™ Percutaneous Tricuspid Annuloplasty System for tricuspid valve […]
NEWTOWN, Pa., March 7, 2019 /PRNewswire/ — Micro Interventional Devices, Inc. (MID) Chairman, President and CEO, Michael Whitman, and OSCOR, Inc. President and CEO, Thomas Osypka, are pleased to announce a strategic alliance that leverages each company’s unique strengths and capabilities to further develop and commercialize innovative solutions to structural heart disease, specifically, MID’s MIA™, Minimally […]
NEWTOWN, Pa., Feb. 20, 2019 /PRNewswire/ — Micro Interventional Devices, Inc. (“MID”) announced today that it is has entered into a Settlement Agreement with Neovasc, Inc. MID (the “Plaintiffs”) filed a lawsuit in September 2018 in the U.S. District Court for the District of New Jersey including certain disputed allegations relating to Neovasc’s transcatheter mitral valve replacement (TMVR) technology […]
NEWTOWN, Pa., Nov. 29, 2018 /PRNewswire/ — Micro Interventional Devices, Inc.™ (MID) announced the continued successful enrollment of patients in STTAR (the Study of Transcatheter Tricuspid Annular Repair) being conducted in Europe. MID’s MIA™, Minimally Invasive Annuloplasty technology, is being studied for its safety and performance in the treatment of severe tricuspid regurgitation. MIA […]
NEWTOWN, Pa., Oct. 12, 2018 /PRNewswire/ — Micro Interventional Devices, Inc.™ (MID) announced today the world’s first percutaneous implantation of its MIA™, Minimally Invasive Annuloplasty, technology for tricuspid and mitral repair. This marks the first patient enrolled in the transcatheter arm of the STTAR (Study of Transcatheter Tricuspid Annular Repair) trial being conducted in Europe. […]
